Fate Therapeutics - FATE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.27
  • Forecasted Upside: 239.40 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.09 (0.47%)

This chart shows the closing price for FATE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FATE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FATE

Analyst Price Target is $65.27
▲ +239.40% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $65.27, with a high forecast of $115.00 and a low forecast of $28.00. The average price target represents a 239.40% upside from the last price of $19.23.

This chart shows the closing price for FATE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Fate Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2022SVB LeerinkSet Target$64.00Low
11/16/2022CitigroupLower TargetBuy$87.00 ➝ $80.00Low
11/4/2022Cantor FitzgeraldReiterated RatingOverweight$98.00 ➝ $45.00N/A
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$42.00Low
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$42.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/9/2022Morgan StanleyLower TargetEqual Weight$45.00 ➝ $35.00Low
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight$90.00Low
8/4/2022OppenheimerLower Target$135.00 ➝ $90.00Low
7/28/2022Needham & Company LLCInitiated CoverageHoldLow
7/11/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$50.00 ➝ $47.00N/A
6/2/2022Robert W. BairdInitiated CoverageNeutral$28.00Low
5/23/2022Piper SandlerLower TargetOverweight$113.00 ➝ $71.00Medium
4/13/2022Truist FinancialLower Target$125.00 ➝ $75.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/4/2022HC WainwrightLower TargetBuy$122.00 ➝ $115.00Low
3/1/2022WedbushBoost TargetOutperform$74.00 ➝ $77.00Medium
1/11/2022HC WainwrightReiterated RatingBuy$122.00High
1/3/2022GuggenheimLower Target$107.00 ➝ $78.00Medium
12/15/2021Morgan StanleyLower TargetEqual Weight$74.00 ➝ $62.00High
12/15/2021HC WainwrightBoost TargetBuy$121.00 ➝ $122.00High
12/15/2021WedbushUpgradeNeutral ➝ Outperform$71.00 ➝ $74.00High
12/7/2021CowenInitiated CoverageOutperformHigh
11/8/2021CitigroupUpgradeNeutral ➝ Buy$94.00 ➝ $87.00Medium
11/8/2021SVB LeerinkLower TargetOutperform$118.00 ➝ $115.00Medium
11/5/2021Roth CapitalLower TargetNeutral$90.00 ➝ $60.00High
8/26/2021Morgan StanleyInitiated CoverageEqual Weight$77.00Low
8/23/2021HC WainwrightReiterated RatingBuy$121.00Medium
8/5/2021HC WainwrightBoost TargetBuy$120.00 ➝ $121.00High
8/5/2021SVB LeerinkLower TargetOutperform$120.00 ➝ $118.00High
7/9/2021Stifel NicolausReiterated RatingBuy$116.00High
6/7/2021HC WainwrightUpgradeNeutral ➝ Buy$120.00High
5/14/2021WedbushDowngradeOutperform ➝ NeutralMedium
5/7/2021WedbushUpgradeNeutral ➝ Outperform$88.00Low
4/26/2021Jefferies Financial GroupInitiated CoverageBuy$145.00Low
3/12/2021SVB LeerinkBoost TargetOutperform$58.00 ➝ $121.00Medium
3/4/2021WedbushReiterated RatingOutperform ➝ NeutralHigh
3/4/2021Wells Fargo & CompanyBoost TargetOverweight$84.00 ➝ $130.00N/A
2/26/2021Truist FinancialBoost Target$85.00 ➝ $135.00Medium
2/26/2021Bank of AmericaInitiated CoverageBuy$115.00High
2/26/2021WedbushDowngradeOutperform ➝ NeutralHigh
2/25/2021Roth CapitalBoost Target$30.00 ➝ $90.00High
2/25/2021Cantor FitzgeraldBoost TargetOverweight$86.00 ➝ $98.00High
2/25/2021MizuhoBoost TargetBuy$88.00 ➝ $109.00High
2/17/2021Piper SandlerBoost TargetOverweight$99.00 ➝ $116.00Low
2/11/2021CitigroupDowngradeBuy ➝ NeutralLow
1/27/2021HC WainwrightReiterated RatingNeutral$108.00Medium
1/25/2021BMO Capital MarketsBoost TargetMarket Perform$57.00 ➝ $88.00Medium
1/19/2021OppenheimerReiterated RatingOutperform$70.00 ➝ $135.00High
1/15/2021BarclaysBoost TargetPositive ➝ Overweight$110.00 ➝ $130.00High
12/21/2020Stifel NicolausBoost TargetBuy$79.00 ➝ $118.00High
12/17/2020BarclaysBoost TargetOverweight$80.00 ➝ $110.00Low
12/8/2020MizuhoBoost TargetBuy$40.00 ➝ $88.00High
12/7/2020BMO Capital MarketsBoost TargetMarket Perform$43.00 ➝ $57.00High
12/7/2020Wells Fargo & CompanyBoost TargetOverweight$61.00 ➝ $84.00High
12/7/2020WedbushBoost TargetOutperform$55.00 ➝ $88.00High
12/7/2020Smith Barney CitigroupBoost Target$63.00 ➝ $76.00High
12/7/2020Piper SandlerBoost TargetOverweight$71.00 ➝ $99.00High
12/7/2020OppenheimerBoost TargetOutperform$60.00 ➝ $70.00High
12/7/2020SVB LeerinkBoost TargetOutperform$34.00 ➝ $58.00High
12/2/2020BarclaysBoost TargetOverweight$60.00 ➝ $70.00Low
11/24/2020Truist FinancialBoost Target$40.00 ➝ $65.00Low
11/9/2020Smith Barney CitigroupBoost Target$40.00 ➝ $63.00Low
11/8/2020OppenheimerBoost TargetOutperform$40.00 ➝ $60.00High
11/6/2020Piper SandlerBoost TargetOverweight$59.00 ➝ $71.00Low
11/6/2020Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $61.00High
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$29.00 ➝ $43.00High
10/15/2020BarclaysBoost TargetOverweight$40.00 ➝ $60.00High
8/13/2020Cantor FitzgeraldBoost TargetOverweight$32.00 ➝ $40.00Low
8/6/2020HC WainwrightReiterated RatingBuy$42.00Medium
8/6/2020OppenheimerReiterated RatingBuy$40.00High
6/9/2020OppenheimerInitiated CoverageBuy$34.00 ➝ $40.00Low
6/9/2020Piper SandlerLower Target$63.00 ➝ $59.00Low
5/13/2020HC WainwrightInitiated CoverageBuy$42.00High
5/12/2020BMO Capital MarketsBoost TargetMarket Perform$28.00 ➝ $29.00High
4/6/2020OppenheimerLower TargetOutperform$36.00 ➝ $34.00Low
4/3/2020Piper SandlerBoost TargetHigh
4/3/2020WedbushBoost TargetOutperform$38.00 ➝ $41.00High
4/3/2020MizuhoReiterated RatingBuy$40.00High
3/4/2020CitigroupBoost TargetBuy$26.00 ➝ $41.00High
3/4/2020BarclaysInitiated CoverageOverweight$40.00High
3/3/2020BMO Capital MarketsBoost Target$22.00 ➝ $28.00High
3/3/2020Roth CapitalBoost Target$20.00 ➝ $30.00High
3/3/2020BTIG ResearchBoost TargetBuy$27.00 ➝ $42.00High
3/3/2020Piper SandlerBoost TargetOverweight$28.00 ➝ $57.00High
3/3/2020GuggenheimBoost TargetBuy$25.00 ➝ $41.00High
3/3/2020OppenheimerBoost TargetOutperform$27.00 ➝ $36.00High
2/26/2020MizuhoBoost TargetBuy$33.00 ➝ $40.00High
2/14/2020WedbushBoost TargetOutperform$29.00 ➝ $33.00Medium
2/12/2020Wells Fargo & CompanyReiterated RatingOverweight$24.00 ➝ $34.00High
1/9/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$22.00High
12/30/2019MizuhoBoost TargetBuy ➝ Buy$27.00 ➝ $33.00High
12/9/2019OppenheimerReiterated RatingBuy$27.00High
12/9/2019BMO Capital MarketsLower TargetOutperform$26.00 ➝ $22.00High
12/9/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$24.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$25.00Low
11/6/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$24.00 ➝ $16.00High
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00High
9/16/2019Piper Jaffray CompaniesLower TargetOverweight$30.00 ➝ $28.00Low
9/4/2019MizuhoReiterated RatingBuy$27.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$27.00High
8/7/2019BMO Capital MarketsSet TargetBuy$27.00High
8/7/2019WedbushBoost TargetOutperform$21.00 ➝ $26.00High
7/22/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$32.00 ➝ $32.00High
7/12/2019CIBCInitiated CoverageOutperform ➝ Outperform$27.00High
7/12/2019OppenheimerInitiated CoverageOutperform$27.00 ➝ $27.00High
6/27/2019Piper Jaffray CompaniesBoost TargetOverweight ➝ Top Pick$23.00 ➝ $30.00High
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$27.00High
6/7/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$20.00 ➝ $20.00Medium
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$20.00 ➝ $26.00Low
3/28/2019SVB LeerinkInitiated CoverageOutperform$20.00Medium
3/6/2019Wells Fargo & CompanyBoost TargetOutperform$18.00 ➝ $24.00High
2/11/2019WedbushBoost TargetOutperform ➝ Outperform$19.00 ➝ $21.00Low
1/3/2019StephensDowngradeOverweight ➝ EqualMedium
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00Low
9/25/2018Piper Jaffray CompaniesReiterated RatingOverweight$23.00High
9/18/2018Piper Jaffray CompaniesReiterated RatingOverweight$25.00High
8/7/2018WedbushReiterated RatingOutperform$19.00High
8/7/2018HC WainwrightReiterated RatingHold$12.00High
8/1/2018CitigroupInitiated CoverageBuy$20.00High
3/29/2018WedbushReiterated RatingOutperform$19.00Low
3/20/2018HC WainwrightReiterated RatingHold$12.00Medium
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
3/6/2018WedbushReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00High
3/6/2018HC WainwrightDowngradeBuy ➝ Neutral$12.00High
3/6/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$7.00 ➝ $20.00High
3/6/2018Wells Fargo & CompanyReiterated RatingOutperform$10.00 ➝ $19.00High
3/6/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Top Pick$20.00High
1/18/2018WedbushReiterated RatingOutperform$10.00 ➝ $7.00Medium
12/18/2017WedbushReiterated RatingOutperform$7.00Low
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$10.00Medium
12/13/2017HC WainwrightReiterated RatingBuy$7.00High
12/12/2017Raymond JamesReiterated RatingBuyMedium
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $19.23
Low: $18.79
High: $19.40

50 Day Range

MA: $20.76
Low: $18.78
High: $23.83

52 Week Range

Now: $19.23
Low: $17.10
High: $66.56


78,848 shs

Average Volume

1,164,206 shs

Market Capitalization

$1.87 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Fate Therapeutics?

The following equities research analysts have issued research reports on Fate Therapeutics in the last year: BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Guggenheim, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, StockNews.com, SVB Leerink LLC, Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for FATE.

What is the current price target for Fate Therapeutics?

15 Wall Street analysts have set twelve-month price targets for Fate Therapeutics in the last year. Their average twelve-month price target is $65.27, suggesting a possible upside of 239.4%. HC Wainwright has the highest price target set, predicting FATE will reach $115.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $28.00 for Fate Therapeutics in the next year.
View the latest price targets for FATE.

What is the current consensus analyst rating for Fate Therapeutics?

Fate Therapeutics currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FATE will outperform the market and that investors should add to their positions of Fate Therapeutics.
View the latest ratings for FATE.

What other companies compete with Fate Therapeutics?

How do I contact Fate Therapeutics' investor relations team?

Fate Therapeutics' physical mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 875-1800 and its investor relations email address is [email protected] The official website for Fate Therapeutics is www.fatetherapeutics.com. Learn More about contacing Fate Therapeutics investor relations.